Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of Asthma~* Reversibility ≥ 12% and ≥200mls reversibility of FEV1 within approximately 30-minutes following 2 to 4 puffs of albuterol~* FEV1 between 40-85% predicted~* Currently on short acting beta2 agonist therapy~Key Exclusion Criteria:~* History of life threatening asthma~* Respiratory Infection or oropharyngeal candidiasis~* Asthma exacerbation~* Uncontrolled disease or clinical abnormality~* Allergies~* Taking another Investigational medications or other prohibited medications

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GW685698X (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).